Sagimet Biosciences, Inc.

As of November 14, 2024, Sagimet Biosciences, Inc. is considered overvalued and has moved from a risky to a "does not qualify" valuation grade due to negative financial metrics, including a price-to-book ratio of 1.23, an ROE of -41.09%, and unfavorable comparisons to peers, despite a recent stock return of 142.32%.

As of June 4, 2025, the trend has shifted to mildly bullish, supported by a bullish MACD and Bollinger Bands, but caution is advised due to mixed signals from daily moving averages and a bearish monthly RSI.

Sagimet Biosciences, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $18 million and a market cap of $211.04 million. Key financial metrics include a negative P/E ratio, a 0.00% dividend yield, and a return on equity of -41.09%.

As of Jun 18, Sagimet Biosciences, Inc. has a market capitalization of 211.04 million and reported net sales of 0.00 million with a net profit of -57.12 million over the last four quarters. The company's balance sheet shows shareholder's funds of 155.81 million and total assets of 160.26 million.